home / stock / govxw / govxw news

GOVXW News and Press, GeoVax Labs Inc. Warrants From 07/20/23

Stock Information
Company Name: GeoVax Labs Inc. Warrants
Stock Symbol: GOVXW
Market: NASDAQ
Website: geovax.com
Menu
GOVXW GOVXW Quote GOVXW Short GOVXW News GOVXW Articles GOVXW Message Board
Get GOVXW Alerts

News, Short Squeeze, Breakout and More Instantly...
GOVXW - GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

Seeking Improved Immune Response vs mRNA Vaccine ATLANTA, GA, July 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced t...
GOVXW - GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference

ATLANTA, GA, July 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of Phase 1/2 clinical trial data ...

GOVXW - GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference

ATLANTA, GA, June 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that an abstract regarding GeoVax’s gene therapy candidate...

GOVXW - GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights

Spotlight Content on Pandemic Preparedness: Getting Ready for the Next “Disease X” ATLANTA, GA, June 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infe...
GOVXW - GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates

ATLANTA, GA, May 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced it has executed a Master Services Agreement (MSA) with Advanced Bi...

GOVXW - GeoVax to Participate in Upcoming Industry Meetings

Management to participate in 2023 ASCO Annual Meeting and 2023 BIO International Convention ATLANTA, GA, May 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapie...

GOVXW - GeoVax's Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients

New and Unpublished Data from Phase 2 Open-Label Safety Study of GEO-CM04S1 Presented at Two Recent Scientific Meetings ATLANTA, GA, May 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and ...
GOVXW - GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings

Presentations to Include New and Unpublished Data from Phase 2 Open-Label Safety Study of GEO-CM04S1 ATLANTA, GA, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against ...

GOVXW - GeoVax Labs to Participate in A.G.P.'s Virtual Healthcare Conference

ATLANTA, GA, May 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will participate in the Alliance Global Partners’ V...

GOVXW - GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update

Cancer Gene Therapy Program and Next-Generation COVID-19 Vaccine Advancing in Phase 2 Clinical Trials Company to Host Conference Call and Webcast Today at 4:30 p.m. ET ATLANTA, GA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire ...
Previous 10 Next 10